Cancer · 1987 · 76 citations · 16 references
MedicineHematologyHematology PhysiologyHematopathologyHemostasisAnticoagulant TherapyAnticoagulation TherapyCoagulation AbnormalitiesCoagulation DisordersCoagulation PhysiologyDisseminated Intravascular CoagulationAcute Disseminated Intravascular CoagulationCancer-associated Disseminated Intravascular CoagulationHeparin AnticoagulationTissue Factor Activation
Tissue factor activity (TFA) of 10(8) leukemia cells was measured in 82 patients with acute nonlymphoid leukemia by the clotting method. The TFA bore a significant correlation to the development of disseminated intravascular coagulation (DIC) in these cases. Mean TFA value with standard deviation (SD) was 8.3 +/- 6.3 U in 48 cases with DIC, which was significantly higher than 0.3 +/- 4.2 U in 34 cases without DIC. Whereas Mean TFA in non-M3 was 0.9 +/- 6.3 U which was significantly lower than 37.2 +/- 2.3 U in M3, some non-M3 showed TFA as high as M3 and were complicated by DIC. In heparin treatment, dosage of heparin could not be controlled by either APTT or AcCT but was controlled by the extent of TFA of leukemia cells. Retrospective analysis of clinical features revealed that 97000X + 9000 units/day (X = logarithm value of TFA) of heparin is an adequate dosage for the successful treatment of DIC when TFA of leukemia cells is 0.8 U or more.
16
John M. Bennett, Daniel Catovsky, Marie‐Theregse Daniel et al. · British Journal of Haematology · 1976 · 5.6K citations
Medicine, Hematology, Pathology +17
Norio Kobayashi, Tadashi Maekawa, M Takada et al. · Current studies in hematology and blood transfusion · 2015 · 313 citations
Medicine, Hematology, Pathology +14
Antithrombin III, Antifactor Xa and Heparin
Rosemary Biggs, K. W. E. Denson, N Akman et al. · British Journal of Haematology · 1970 · 196 citations
Medicine, Biochemistry, Hematology +14